Skip to main content
SpringerLink
Log in

Intranasally and orally active GH secretagogues are useful clinical tools: So why are they not on the market?

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Laron Z. Growth hormone secretagogues: Clinical experience and therapeutic potential. Drugs 1995, 50: 595–601.

    Article  PubMed  CAS  Google Scholar 

  2. Bowers C.Y., Momany F., Reynolds G.A., Chang D., Hong A., Chang K. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1980, 106: 663–667.

    Article  PubMed  CAS  Google Scholar 

  3. Bowers C.Y., Sartor A.D., Reynolds G.A., Badger T.M. On the actions of the growth hormone-releasing hexapeptide GHRP. Endocrinology 1991, 128: 2027–2035.

    Article  PubMed  CAS  Google Scholar 

  4. Deghenghi R., Cananzi M.M., Torsello A., Battisti C., Muller E.E., Locatelli V. GH-releasing activity of Hexarelin. A new growth hormone releasing peptide in infant and adult rats. Life Sci. 1994, 54: 1321–1328.

    Article  PubMed  CAS  Google Scholar 

  5. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone (GH)-releasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.

    Article  PubMed  CAS  Google Scholar 

  6. Ghigo E., Boghen M., Casanueva F.F., Dieguez C. Growth hormone secretagogues: Basic findings and clinical implications. Elsevier Science B.V. Holland, 1999.

    Google Scholar 

  7. Howard A.D., Feighner S.D., Cully D.F., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 16: 974–977.

    Article  Google Scholar 

  8. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656–660.

    Article  PubMed  CAS  Google Scholar 

  9. Laron Z., Bowers C.Y., Hirsch D., et al. Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents. Acta Endocrinol. 1993, 129: 424–426.

    PubMed  CAS  Google Scholar 

  10. Laron Z., Frenkel J., Silbergeld A. Growth hormone-releasing peptide - Hexarelin - in children: Biochemical and growth promoting effects, Chapter 24. In: Bercu B.B., Walker R.F. (Eds.), Growth hormone secretagogues. Springer Verlag, New York, 1996, p. 379.

    Chapter  Google Scholar 

  11. Korbonitz M., Kaltsas G, Perry L.A., et al. Hezarelin as a test of pituitary reserve in patients with pituitary disease. Clin. Endocrinol. 1999, 51: 369–375.

    Article  Google Scholar 

  12. Laron Z., Frenkel J., Deghenghi R., Anin S., Klinger B., Silbergeld A. Intranasal administration of the GHRP — Hexarelin accelerates growth in short children. Clin. Endocrinol. 1995, 43: 631–635.

    Article  CAS  Google Scholar 

  13. Klinger B., Silbergeld A., Deghenghi R., Frenkel J., Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur. J. Endocrinol. 1996, 134: 716–719.

    Article  PubMed  CAS  Google Scholar 

  14. Pihoker C., Badger T.M., Reynolds G.A., Bowers C.Y. Intranasal growth hormone (GH) releasing peptide-2 (GHRP-2) in children with GH deficiency: Growth effects and GH secretion studies during treatment. Abstract P3-54 10th International Congress of Endocrinology, San Francisco, 1996, p. 768.

    Google Scholar 

  15. Sibilia V., Cocchi D., Pagani F., et al. Hexarelin, a growth hormone-releasing peptide, counteracts bone loss in gonadectomized male rats. GH and IGF Res. 1999, 9: 219–227.

    CAS  Google Scholar 

  16. Van den Berghe G., Baxter R.C., Weekers F., et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin. Endocrinol. 2002, 56: 655–669.

    Article  Google Scholar 

  17. Cummings D.E., Weigle D.S., Frayo S., et al. Plasma Ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 2002, 346: 1623–1630.

    Article  PubMed  Google Scholar 

  18. Gasperi M., Aimaretti G., Scarcello C., et al. Low dose Hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. J. Clin. Endocrinol. Metab. 1999, 84: 2633–2637.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology and Diabetes Research Unit, Schneider Children’s Medical Center of Israel, Israel

    Zvi Laron

  2. WHO Collaborating Center for the Study of Diabetes in Youth, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Zvi Laron

Authors
  1. Zvi Laron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zvi Laron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laron, Z. Intranasally and orally active GH secretagogues are useful clinical tools: So why are they not on the market?. J Endocrinol Invest 26, 91–92 (2003). https://doi.org/10.1007/BF03345130

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345130

Key-words

Search

Navigation